Jefferies Financial Group Inc. Takes $7.37 Million Position in Insulet Corporation $PODD

Jefferies Financial Group Inc. bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 48,416 shares of the medical instruments supplier’s stock, valued at approximately $7,371,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. BlackRock Inc. bought a new position in shares of Insulet during the 2nd quarter worth approximately $1,018,582,000. State Street Corp increased its stake in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after acquiring an additional 65,317 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. lifted its position in shares of Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares during the period.

Insulet Trading Up 0.0%

NASDAQ:PODD opened at $143.41 on Friday. The company has a market cap of $9.95 billion, a PE ratio of 26.81, a PEG ratio of 1.13 and a beta of 1.10. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The firm has a 50-day moving average of $154.47 and a 200-day moving average of $181.40. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the previous year, the firm earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. Leerink Partners lowered shares of Insulet from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $247.00 to $145.00 in a report on Thursday, August 6th. Raymond James Financial reissued an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Stifel Nicolaus reduced their target price on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Sanford C. Bernstein decreased their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $195.40.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.36% of the company’s stock.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.